Results 31 to 40 of about 4,156,285 (177)

NQO1/p65/CXCL12 Axis‐Recruited Tregs Mediate Resistance to Anti‐PD‐1 Plus Lenvatinib Therapy in PIVKA‐II‐Positive Hepatocellular Carcinoma [PDF]

Advanced Science
Immune checkpoint inhibitors (ICIs) combined with anti‐angiogenic agents manifest improved survival in advanced hepatocellular carcinoma (HCC), but responses remain heterogeneous.
Biao Gao, Yafei Wang, Zhuoya Sun, Haowen Tang, Yinbiao Cao, Hao Jiang, Wenwen Zhang, Yinzhe Xu, Bingyang Hu, Zhe Liu, Guankun Mao, Xuerui Li, Junfeng Li, Tao Wan, Bing Liu, Xiao Zhao, Shunchang Jiao, Chonghui Li, Shichun Lu   +18 more
doaj   +2 more sources

Immunohistochemical studies of PIVKA-II in hepatocellular carcinoma by indirect immunofluorescence.

Acta medica Okayama, 1995
Tissue PIVKA-II was examined in 32 hepatocellular carcinomas and 2 metastatic liver tumors using indirect immunofluorescence, and the results were compared with the size, histological grading and serum PIVKA-II level. The specificity of this method was confirmed by the disappearance of reactivity in PLC/PRF/5 cells after the addition of vitamin K to ...
Kuwahara, Naoaki, Higashi, Toshihiro, Nouso, Kazuhiro, Ito, Toshio, Tsuji, Takao   +4 more
openaire   +4 more sources

Combining AFP, PIVKA-II, and GP73 has diagnostic utility for hepatitis B-associated hepatocellular carcinoma and is consistent with liver pathology results [PDF]

Scientific Reports
Although liquid biopsy has garnered increasing attention in recent years for diagnosing hepatocellular carcinoma (HCC), serum biomarkers continue to hold significant value for HCC diagnosis due to their simple operation, cost-effectiveness, and high ...
Hu Rui, Ni Yueqin, Wang Wei, Li Bangtao, Xiao Li   +4 more
doaj   +2 more sources

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

PLoS ONE, 2022
Background Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). Although the development of systemic therapies for advanced HCC has been remarkable, the role of PIVKA ...
Shun Kaneko, Masayuki Kurosaki, Kaoru Tsuchiya, Yutaka Yasui, Yuka Hayakawa, Kento Inada, Yuki Tanaka, Shun Ishido, Sakura Kirino, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Yuka Takahashi, Hiroyuki Nakanishi, Namiki Izumi   +20 more
doaj   +2 more sources

ПОКАЗНИКИ ПРОТРОМБІНОВОГО КОМПЛЕКСУ ТА PIVKA-II У ДІТЕЙ ПЕРШИХ 6 МІСЯЦІВ ЖИТТЯ, ЩО ПЕРЕБУВАЮТЬ НА ГРУДНОМУ ВИГОДОВУВАННІ

Неонатологія, хірургія та перинатальна медицина, 2017
Метою нашого дослідження було вивчення вітамін-К-залежних показників протромбінового комплексу гемостазу і змісту субстанції PIVKA-II, як маркера дефіциту вітаміну К, у дітей, які отримують грудне вигодовування від народження до 6 місяців життя ...
O. G. Ivanko, O. V. Solianik
doaj   +2 more sources

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma

BMC Cancer, 2021
Background Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system and has high morbidity and mortality rates. It is essential to search new biomarkers to improve the accuracy of early HCC diagnosis.
Honglei Feng, Bole Li, Ze Li, Qian Wei, Li Ren   +4 more
doaj   +1 more source

Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma

Journal of the Formosan Medical Association, 2022
Background/purpose: Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is a diagnostic marker for hepatocellular carcinoma (HCC). Transarterial chemoembolization (TACE) is the standard management for intermediate stage HCC but lacks ...
Sung-Yin Wang, Tung-Hung Su, Bang-bin Chen, Chun-Jen Liu, Chen-Hua Liu, Hung-Chih Yang, Tai-Chung Tseng, Pei-Jer Chen, Jia-Horng Kao   +8 more
doaj   +1 more source

Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma

Frontiers in Oncology, 2021
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related death worldwide. Due to the lack of efficient tools for early detection, asymptomatic HCC patients are diagnosed at an advanced stage, leading to
Yang Yang, Yang Yang, Guangbing Li, Ziwen Lu, Ziwen Lu, Yong Liu, Junjie Kong, Jun Liu, Jun Liu   +8 more
doaj   +1 more source

Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis

JGH Open, 2022
Background and Aims Prothrombin induced by vitamin K absence‐II (PIVKA‐II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha‐fetoprotein (AFP) for early disease detection.
Henry L Y Chan, Arndt Vogel, Thomas Berg, Enrico N De Toni, Masatoshi Kudo, Jörg Trojan, Anja Eiblmaier, Hanns‐Georg Klein, Johannes Kolja Hegel, Ashish Sharma, Kairat Madin, Vinzent Rolny, Marcus‐Rene Lisy, Teerha Piratvisuth   +13 more
doaj   +1 more source

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

BMC Cancer, 2021
Background Few biomarkers can predict the efficiency of PD-1 blockade in patients with hepatocellular carcinoma (HCC). This study aimed to investigate the prognostic role of AFP and PIVKA-II in HCC patients receiving anti-PD-1 immunotherapy.
Xuqi Sun, Jie Mei, Wenping Lin, Ziliang Yang, Wei Peng, Jinbin Chen, Yaojun Zhang, Li Xu, Minshan Chen   +8 more
doaj   +1 more source